Oryokot Bonniface, Oluka Abraham Ignatius, Kagimu David, Miya Yunus, Ssentongo Saadick Mugerwa, Achola Catherine, Kawuba Abubaker, Mafabi Twaha, Odoi Charles, Bakashaba Baker, Mugisha Kenneth, Etukoit Michael Bernard, Namusoke-Magongo Eleanor
AIDS Information Center, Kampala, Uganda.
University of Suffolk, Ipswich, UK.
AIDS Res Ther. 2025 May 20;22(1):52. doi: 10.1186/s12981-025-00750-8.
Adolescents living with HIV (ALHIV) aged 10-19 years endure sub-optimal viral load suppression (VLS) and retention in care in many settings. We implemented operation triple zero (OTZ) in The AIDS Support Organization (TASO) Soroti and Mbale Centers of Excellence (COEs) to improve VLS and retention. Thus, this study evaluated the contribution of OTZ to improving both treatment outcomes among the ALHIV in the two COEs at one year.
This before and after study used Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework to guide secondary data collection from the cohort of ALHIV active in care in the April-June 2022 quarter. Effectiveness was determined by computing the overall VLS rates basing on plasma RNA copies below 1000/ml while retention was based on being active in care at the end of June 2024. A self-report was used to gather fidelity data. Univariates were summarized as frequencies and proportions, Generalized Equation Estimate (GEE) to compute the effect of the model and associated factors at 95% confidence interval and P < 0.05 level of significance. Odds ratio was used to report levels of predictability.
Out of the original 533 ALHIV, 510 were considered for the post-intervention analysis, 53.1% females, mean age of 15.27 (Standard deviation = 2.15). Overall, retention at 12 months improved from 95.9 to 97.3% while VLS from 84 to 92.7% [adjusted OR 1.26 95%CI (0.61-2.61) P = 0.036]. Importantly, there was zero death in the one year of implementation. After adjusting for confounders, adolescents in the facility-based group (FBG) were more likely to be retained in care [adjusted odds ratio (aOR)7.36 95% CI (2.35-23.10) P = 0.001]. Also, multi-month dispensing [aOR 11.65 95%CI (2.93-46.34) P < 0.001] and being in FBG [aOR 9.87 95%CI (4.08-23.88) P < 0.001] and community-based models [aOR 21.96 95%CI (2.68-179.84) P = 0.004] were predictive of good VLS while poor adherence [aOR 0.02 95%CI (0.0037-0.11) P < 0.001] and being male [aOR 0.5 95%CI (0.27-0.91) p = 0.024] were predictors of poor VLS. Fidelity was good, at 80%.
OTZ contributed to improved VLS in the setting possibly due to fidelity of enhanced implementation of adolescent friendly health services. We encourage OTZ adaptation in similar settings to strengthen improvements in VLS.
在许多地方,10至19岁的感染艾滋病毒青少年(ALHIV)的病毒载量抑制(VLS)情况欠佳,且在接受治疗时的留存率较低。我们在艾滋病支持组织(TASO)索罗蒂和姆巴莱卓越中心(COE)实施了“零三联行动”(OTZ),以改善病毒载量抑制和留存情况。因此,本研究评估了OTZ在一年时间里对改善这两个卓越中心的ALHIV治疗效果的贡献。
本项前后对照研究采用“覆盖、效果、采纳、实施和维持”(RE-AIM)框架,指导从2022年4月至6月季度接受治疗的ALHIV队列中收集二手数据。通过计算血浆RNA拷贝数低于1000/ml的总体病毒载量抑制率来确定效果,而留存率则基于在2024年6月底仍在接受治疗。通过自我报告收集保真度数据。单变量以频率和比例进行汇总,使用广义方程估计(GEE)计算模型效果及相关因素,置信区间为95%,显著性水平为P<0.05。使用优势比报告可预测性水平。
在最初的533名ALHIV中,510名被纳入干预后分析,其中女性占53.1%,平均年龄为15.27岁(标准差=2.15)。总体而言,12个月时的留存率从95.9%提高到了97.3%,而病毒载量抑制率从84%提高到了92.7%[调整后的优势比为1.26,95%置信区间(0.61-2.61),P=0.036]。重要的是,在实施的一年中无死亡病例。在对混杂因素进行调整后,机构照护组(FBG)的青少年更有可能继续接受治疗[调整后的优势比(aOR)为7.36,95%置信区间(2.35-23.10),P=0.001]。此外,多月份配药[aOR为11.65,95%置信区间(2.93-46.34),P<0.001]、处于FBG组[aOR为9.87,95%置信区间(4.08-23.88),P<0.001]和社区照护模式[aOR为21.96,95%置信区间(2.68-179.84),P=0.004]可预测良好的病毒载量抑制,而依从性差[aOR为0.02,95%置信区间(0.0037-0.11),P<0.001]和男性[aOR为0.5,95%置信区间(0.27-0.91),P=0.024]则是病毒载量抑制不佳的预测因素。保真度良好,为80%。
OTZ有助于在该环境中改善病毒载量抑制,这可能归因于加强实施青少年友好型健康服务的保真度。我们鼓励在类似环境中采用OTZ,以强化病毒载量抑制方面的改善。